Guest: Keith Flaherty, MD

Guest: Omid Hamid, MD

Through the discussion of two actual case reviews, clinicians viewing or listening to this program will learn how to incorporate immunotherapy with anti-CTLA-4 and PD-1 inhibitors into their clinical practice, evaluate the merits of single-agent vs. sequential immunotherapy regimens, and assess emerging data supporting combination immunotherapy in select patients with melanoma. Listen to and view additional case discussions in Melanoma This activity was made possible through an educational grant from Merck.